A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

ABSTRACT: This study is designed to primarily evaluate the safety and efficacy of U3-1402 in participants with advanced or metastatic colorectal cancer (CRC) who have received at least 2 prior lines of therapy and will explore clinical benefit according to human epidermal growth factor receptor 3 (HER3) tumor expression level in otherwise refractory tumors.

DISEASE(S): Metastatic Colorectal Cancer,Colorectal Neoplasms,Advanced Or Metastatic Colorectal Cancer (crc) Which Is Resistant, Refractory, Or Intolerant To At Least 2 Prior Lines Of Therapy, That Must Include All Of The Following Agents: Fluoropyrimidine, Irinotecan, Platinum Agent, An Anti-epidermal Growth Factor Receptor (egfr) Agent (if Clinically Indicated), An Anti-vascular Endothelial Growth Factor (vegf) Agent (if Clinically Indicated), An Immune Checkpoint Inhibitor (if Clinically Indicated), And A Braf Inhibitor (if Clinically Indicated).

PROVIDER: 2346224 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR